Company news
CorMedix Inc. news in 2023
CorMedix Inc.'s news releases, calls and decks from 2023, newest first.
CorMedix Inc. Announces Appointment of Chief Legal Officer
December 14, 2023
CorMedix Inc. Announces Partnership With The Leapfrog Group
December 3, 2023
CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients
November 14, 2023
CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update
November 13, 2023
CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
November 1, 2023
CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
October 10, 2023
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
September 25, 2023
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
September 7, 2023
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
September 5, 2023
CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath
August 29, 2023
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
August 7, 2023
CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023
July 25, 2023
CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 27, 2023
CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants
June 27, 2023
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
June 20, 2023
Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections
June 14, 2023
Cormedix Inc. To Present At The Jefferies Healthcare Conference
May 29, 2023
CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
May 15, 2023
CorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
May 14, 2023
CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023
May 7, 2023
CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath
April 30, 2023
CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates
April 25, 2023
Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors
April 16, 2023
CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 29, 2023
Cormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update on March 30, 2023
March 20, 2023
CorMedix Inc. Announces Regulatory and Manufacturing Updates
March 1, 2023
CorMedix Inc. Announces Promotions in Commercial and Tech Ops
January 16, 2023
Calls in 2023
Decks in 2023
- Investor Presentation (June 2023)
Investor deck · 22 slides · June 2023
- Investor Presentation (May 2023)
Investor deck · 22 slides · May 2023